Citations

Clear

350 citation(s) found for "Stevens, V".

The Use of Empathic Communication During the COVID-19 Outbreak
Stevens, Sheila K., Brustad, Rebecca, Gilbert, Lena, Houge, Benjamin J., Milbrandt, Timothy, Munson, Karee, Packard, Jennifer, Werneburg, Brooke L., Siddiqui, Mustaqeem , Siddiqui, Mustaqeem A , Packard, Jennifer

Mayo Clinic

Journal of Patient Experience | October 5, 2020 | Volume: 7 | Issue: 5 | Pages: 648-652

10.1177/2374373520962602 | PMID 33294593 Get It

As of May 13, 2020, the number of confirmed SARS-CoV-2 (novel corona virus, COVID-19) infections has risen to 4 300 000 worldwide, with over 1 300 000 confirmed cases in the United States. Various prediction models of spread indicate more hospitalization, increased ventilator use, and the shifting of medical resources to most efficiently serve the patient’s needs. Additionally, mitigation strategies such as monitoring for symptoms, social distancing, safer at home, and the wearing of masks caused our institution to implement significant operational changes to our usual practice. This included screening patients and staff for symptoms, rescheduling routine medical visits, postponing procedures, converting face-to-face visits to telephone or video visits, and changing visitor visit policies. In this article, we describe the various ways we deployed empathic communication messaging and resources across the institution during the COVID-19 pandemic.
Hypofractionated Proton Beam Radiotherapy in Patients With Unresectable Liver Tumors: Multi-institutional Prospective Results From the Proton Collaborative Group
Parzen, Jacob S. , Hartsell, William F. , Chang, John P., Molitoris, Jason K. , Durci, Michael, Urbanic, James J., Ashman, Jonathan B. , Vargas, Carlos , Stevens, Craig, Kabolizadeh, Peyman, Apisarnthanarax, Smith , Tsai, Henry K.

Mayo Clinic

No container title available | September 8, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-70862/v1 Get It

Abstract Background: Recent advances in radiotherapy techniques have allowed ablative doses to be safely delivered to inoperable liver tumors. In this setting, proton beam radiotherapy (PBT) provides the means to escalate radiation dose to the target volume while sparing the uninvolved liver. This study evaluated the safety and efficacy of hypofractionated PBT for liver tumors, predominantly hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC).Methods: We evaluated the prospective registry of the Proton Collaborative Group for patients undergoing definitive PBT for liver tumors. Demographic, clinicopathologic, toxicity, and dosimetry information were compiled.Results: To date, 63 patients have been treated at 9 institutions between 2013-2019. Thirty (48%) had HCC and 25 (40%) had ICC. The median dose and biological equivalent dose (BED) delivered was 58.05 GyE (range, 32.5-75) and 80.5 GyE (range, 53.6-100), respectively. The median mean liver BED was 13.9 GyE. Three (4.8%) patients experienced at least one grade ³3 toxicity. With median follow-up of 5.1 months (range, 0.1-40.8), the local control (LC) rate at 1 year was 91.2% for HCC and 90.9% for ICC. The 1-year LC was significantly higher (95.7%) for patients receiving BED greater than 75.2 GyE than for patients receiving BED of 75.2 GyE or lower (84.6%, p = 0.029). The overall survival rate at 1 year was 65.6% for HCC and 81.8% for ICC. Conclusions: Hypofractionated PBT results in excellent LC, sparing of the uninvolved liver, and low toxicity, even in the setting of dose-escalation. Higher dose correlates with improved LC, highlighting the importance of PBT especially in patients with recurrent or bulky disease.
Abstract PR05: A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans
Du, Zhaohui , Weinhold, Niels , Song, Gregory, Rand, K.A., Hwang, Amie E. , Sheng, Xin , Hom, Victor, Pawlish, Karen , Peters, Edward , Mohrbacher, Ann, Stram, Alexander , Berndt, Sonja I. , Blot, William J. , Stevens, Victoria L. , Goodman, Phyllis J. , Hennis, Anselm , Nemesure, Barbara , Stanford, Janet L. , Witte, John S. , Signorello, Lisa B., John, Esther M. , Stroup, Antoinette M. , Zangari, Maurizio , Zheng, Wei , Hu, Jennifer J. , Carpten, John D. , Mehta, Jayesh, Wolf, Jeffrey L. , Martin, Thomas G. , Terebelo, Howard R. , Janakiraman, Nalini, Kolonel, Laurence N. , Auclair, Daniel , Vij, Ravi , Bernal‐Mizrachi, Leon , Zonder, Jeffrey A. , Huff, Carol Ann , Conti, David V. , Haiman, Christopher A. , John, Esther M , Zheng, Wei , Conti, David V , Berg, David Van Den , Ailawadhi, Sikander , Nooka, Ajay K. , Singhal, Seema , Bock, Cathryn Hufford , Stram, Alex , Casey, Graham , Kittles, Rick A. , Diver, W. Ryan , Klein, Eric A. , Rybicki, Benjamin A. , Bernstein, Leslie , Stephens, Owen , Rhee, Frits van , Olshan, Andrew F. , Ziegler, Regina G. , Nyante, Sarah J. , Ingles, Sue A. , Press, Michael F. , Chanock, Stephen Jacob , Colditz, Graham A. , Tomasson, Michael H. , Fiala, Mark A. , Anderson, Kenneth C. , Marchand, Loı̈c Le , Chiu, Brian C.‐H. , Ziv, Elad , Stram, Daniel O. , Morgan, Gareth J. , Lonial, Sagar , Orlowski, Robert Z. , Cozen, Wendy

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 1, 2020 | Volume: 29 | Issue: 6_Supplement_2 | Pages: PR05-PR05

10.1158/1538-7755.disp19-pr05 Get It

Abstract Background: Persons of African ancestry (AA) experience a 1.5-2-fold risk of multiple myeloma (MM) compared to persons of European ancestry (EA). We assembled a set of MM patients with self-reported AA in order to evaluate the contribution of genetics to etiology in this high-risk group. Methods: Here we present the results of a meta-analysis of two GWAS in 1,813 cases and 8,871 controls of AA. We also conducted an admixture mapping scan to identify risk alleles associated with local ancestry, fine-mapped the 23 known susceptibility loci to find markers that could better capture MM risk in individuals of AA, and constructed a polygenic risk score (PRS) to assess the aggregated effect of known MM risk alleles. Finally, we conducted an eQTL analysis measuring gene expression in those genes harboring a risk variant in malignant plasma cells from 292 of the patients from a single site. Results: In GWAS analysis, we identified two suggestive novel loci located at 9p24.3 and 9p13.1 at P<1 × 10-6, but no genome-wide significant association was noted. In admixture mapping, we observed a genome-wide significant inverse association between local AA at 2p24.1-23.1 and MM risk in AA individuals. 20 of the 23 known EA risk variants showed directional consistency and 9 replicated at P<0.05 in AA individuals. In eight regions, we identified markers that better capture MM risk in persons of AA. AA individuals with a PRS in the top 10% had a 1.82-fold (95%CI: 1.56, 2.11) increased MM risk compared to those with average risk (25-75%). The strongest functional association was between the risk allele for variant rs56219066 at 5q15 and lower ELL2 expression (P= 5.1 × 10–12). Conclusion: Our study shows that common genetic variation contributes to MM risk individuals of AA. This abstract is also being presented as Poster C040. Citation Format: Zhaohui Du, Niels Weinhold, Gregory Chi Song, Kristen A. Rand, David J. Van Den Berg, Amie E. Hwang, Xin Sheng, Victor Hom, Sikander Ailawadhi, Ajay K. Nooka, Seema Singhal, Karen Pawlish, Edward Peters, Cathryn Bock, Ann Mohrbacher, Alexander Stram, Sonja I. Berndt, William J. Blot, Graham Casey, Victoria L. Stevens, Rick Kittles, Phyllis J. Goodman, W. Ryan Diver, Anselm Hennis, Barbara Nemesure, Eric A. Klein, Benjamin A. Rybicki, Janet L. Stanford, John S. Witte, Lisa Signorello, Esther M. John, Leslie Bernstein, Antoinette Stroup, Owen W. Stephens, Maurizio Zangari, Frits Van Rhee, Andrew Olshan, Wei Zheng, Jennifer J. Hu, Regina Ziegler, Sarah J. Nyante, Sue Ann Ingles, Michael Press, John David Carpten, Stephen Chanock, Jayesh Mehta, Graham A Colditz, Jeffrey Wolf, Thomas G. Martin, Michael Tomasson, Mark A. Fiala, Howard Terebelo, Nalini Janakiraman, Laurence Kolonel, Kenneth C. Anderson, Loic Le Marchand, Daniel Auclair, Brian C.-H. Chiu, Elad Ziv, Daniel Stram, Ravi Vij, Leon Bernal-Mizrachi, Gareth J. Morgan, Jeffrey A. Zonder, Carol Ann Huff, Sagar Lonial, Robert Z. Orlowski, David V. Conti, Christopher A. Haiman, Wendy Cozen. A meta-analysis of genome-wide association study and eQTL analysis of multiple myeloma among African Americans [abstract]. In: Proceedings of the Twelfth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2019 Sep 20-23; San Francisco, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2020;29(6 Suppl_2):Abstract nr PR05.
Out of Sight but Not Out of Mind: Caring for Patients Receiving OPAT During the SARS-CoV-2 Pandemic
Rivera, Christina G. , Mahoney, Monica V. , Saleh, Omar Abu , Abu Saleh, Omar , Rivera, Christina G , Mahoney, Monica V , Stevens, Ryan W.

Mayo Clinic

Open Forum Infectious Diseases | July 21, 2020 | Volume: 7 | Issue: 8 | Pages: No page available

10.1093/ofid/ofaa309 | PMID 32782914 Get It

AbstractIn an effort to “flatten the curve” of SARS-CoV-2, society is urged to practice social distancing. However, the management of other disease states may require some patients to undergo outpatient parenteral antimicrobial therapy (OPAT). Practical considerations for OPAT management during an infectious pandemic are reviewed. These include shortening durations of therapy, utilizing the oral route, avoiding medications requiring therapeutic drug monitoring, selecting antimicrobials with long durations, decreasing frequency of laboratory blood draws, and performing tele-health visits.
CERTL Reduces C16 Ceramide, Amyloid-β Levels and Inflammation in a Model of Alzheimer's Disease
Luo, Qian , Stevens, Jo , Giovagnoni, Caterina, Bode, Gerard H., Hobo, Barbara , Scheithauer, Anna-Lena, Hove, Daniël L.A. van den, Verhaagen, Joost , Bieberich, Erhard , Crivelli, Simone Mwenda , Kruining, Daan van , Hoedt, Sandra den , Walter, Jochen , Mulder, Monique T , Exley, Christopher , Mielke, Michelle M. , Vries, Helga E. de , Wouters, Kristiaan , Berkeš, Dušan , Ledesma, María Dolores , Losen, Mario , Martínez‐Martínez, Pilar

Mayo Clinic

No container title available | July 16, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-42740/v1 Get It

Abstract Background: Deregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers, crucial for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.Methods: The plasmid expressing CERTL, the long isoform of CERTs, was used to study the interaction of CERTL with amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescence in HEK cells. The recombinant CERTL protein was employed to study interaction of CERTL with amyloid-β (Aβ), Aβ aggregation process in presence of CERTL, and the resulting changes in Aβ toxicity in neuroblastoma cells. CERTL was overexpressed in neurons by adeno associated virus (AAV) in a familial mouse model of familial AD (5xFAD). Ten weeks after transduction animal were challenged with behavior tests for memory, anxiety and locomotion. At week twelve brains were investigated for sphingolipid levels by mass spectrometry, plaques and neuroinflammation by immunohistochemistry, gene expression and/or immunoassay.Results: Here, we report that CERTL, binds to APP, modifies Aβ aggregation and reduces Aβ neurotoxicity in vitro. Furthermore, we show that intracortical injection of AAV, mediating the expression of CERTL, decreases levels of ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male transgenic mice, modelling familial AD (5xFAD). CERTL in vivo over-expression has a mild effect on animal locomotion and decreases Aβ formation and modulates microglia by decreasing their pro-inflammatory phenotype.Conclusion: Our results demonstrate a crucial role of CERTL in regulating ceramide levels in the brain, in amyloid plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and other neurodegenerative diseases.
CERTL Reduces C16 Ceramide, Amyloid-β Levels and Inflammation in a Model of Alzheimer's Disease
Luo, Qian , Stevens, Jo , Giovagnoni, Caterina, Bode, Gerard H., Hobo, Barbara , Scheithauer, Anna-Lena, Hove, Daniël L.A. van den, Verhaagen, Joost , Bieberich, Erhard , Crivelli, Simone Mwenda , Kruining, Daan van , Hoedt, Sandra den , Walter, Jochen , Mulder, Monique T , Exley, Christopher , Mielke, Michelle M. , Vries, Helga E. de , Wouters, Kristiaan , Berkeš, Dušan , Ledesma, María Dolores , Losen, Mario , Martínez‐Martínez, Pilar

Mayo Clinic

No container title available | June 15, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-33901/v1 Get It

Abstract Background: Deregulation of ceramide and sphingomyelinlevels have been suggested tocontribute tothe pathogenesis of Alzheimer’s disease (AD).Ceramide transfer proteins (CERTs) are ceramide carriers, crucial for ceramide and sphingomyelin balance in cells.Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.Methods: The plasmid expressing CERTL, the long isoform of CERTs, was used to study the interaction of CERTLwith amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescencein HEK cells.The recombinant CERTL protein wasemployed to study interaction of CERTLwith amyloid-β (Aβ), Aβ aggregation process in presence of CERTL, and the resulting changes inAβ toxicity in neuroblastoma cells. CERTLwas overexpressed in neurons by adeno associatedvirus (AAV) in a familial mouse model of familial AD (5xFAD). Ten weeks after transduction animal were challenged with behavior tests for memory, anxiety and locomotion. At week twelve brains were investigated for sphingolipid levels by mass spectrometry, plaques and neuroinflammation by immunohistochemistry, gene expression and/or immunoassay.Results:Here, we report that CERTL, binds to APP, modifies Aβ aggregation and reduces Aβ neurotoxicity in vitro. Furthermore, we show that intracortical injection of AAV, mediating the expression of CERTL, decreases levels of ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male transgenic mice, modelling familial AD (5xFAD). CERTLin vivo over-expression hasa mild effect on animal locomotion and decreases Aβ formation and modulates microglia by decreasing their pro-inflammatory phenotype.Conclusion: Our results demonstratea crucial role of CERTL in regulatingceramidelevels in the brain, in amyloid plaque formation and neuroinflammation,thereby opening research avenuesfor therapeutic targets of AD and other neurodegenerative diseases.
Physical Therapist Management of Total Knee Arthroplasty
Jette, Diane U., Burkett, Lynn, Langham, Bud, Logerstedt, David , Piuzzi, Nicolás S. , Poirier, Noreen M, Radach, Linda J L, Ritter, Jennifer, Tompkins, James, Zeni, Joseph , Hunter, Stephen J, Ritter, Jennifer E, Scalzitti, David A. , Stevens‐Lapsley, Jennifer E.

Mayo Clinic

Physical Therapy | June 4, 2020 | Volume: 100 | Issue: 9 | Pages: 1603-1631

10.1093/ptj/pzaa099 | PMID 32542403 Get It

Abstract A clinical practice guideline on total knee arthroplasty was developed by an American Physical Therapy (APTA) volunteer guideline development group that consisted of physical therapists, an orthopedic surgeon, a nurse, and a consumer. The guideline was based on systematic reviews of current scientific and clinical information and accepted approaches to management of total knee arthroplasty.
Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors
Singh, Nina, Winston, Drew J., Lyon, G. Marshall, Silveira, Fernanda P. , Wagener, Marilyn M., Edmison, Bradley, Razonable, Raymund R. , Stevens‐Ayers, Terry , Boeckh, Michael , Limaye, Ajit P.

Mayo Clinic

JAMA | April 14, 2020 | Volume: 323 | Issue: 14 | Pages: 1378

10.1001/jama.2020.3138 | PMID 32286644 Get It

One‐carbon metabolism‐related micronutrients intake and risk for hepatocellular carcinoma: A prospective cohort study
Antwi, Samuel O. , Petrick, Jessica L. , Norez, Daniel, Stevens, Victoria L. , Liao, Linda M. , Roberts, Lewis R. , McGlynn, Katherine A. , McGlynn, Katherine A , Roberts, Lewis R , Antwi, Samuel O , Campbell, Peter T. , Patel, Tushar

Mayo Clinic

International Journal of Cancer | April 14, 2020 | Volume: 147 | Issue: 8 | Pages: 2075-2090

10.1002/ijc.33007 | PMID 32285447 Get It

AbstractDeficient intake of micronutrients involved in one‐carbon metabolism (eg, choline, methionine, vitamin B12 and folic acid) leads to hepatocellular carcinoma (HCC) development in rodents, but is under‐investigated in humans. We investigated the association between one‐carbon metabolism‐related micronutrient intake and HCC risk in a prospective cohort of 494 860 participants with 16 years of follow‐up in the NIH‐AARP study. Dietary intakes and supplement use were ascertained at baseline using a food‐frequency questionnaire. Total intake (diet plus supplements) of the following one‐carbon metabolism‐related micronutrients were calculated: folate, methionine and vitamins B2 (riboflavin), B3 (niacin), B6 and B12. These micronutrients were examined both individually and simultaneously, with adjustment for covariates. Cox proportional hazard models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). Over the 16‐year follow‐up period, 647 incident HCC cases were diagnosed. When examined individually, higher total vitamin B3 intake was associated with a lower HCC risk (HRQ5 vs Q1 = 0.60; 95% CI = 0.42‐0.85; Ptrend = .008), and the association remained significant when all six micronutrients were examined simultaneously (HRQ5 vs Q1 = 0.32; 95% CI = 0.18‐0.55; Ptrend < .0001). Among participants with >3 years of follow‐up, higher total vitamin B3 intake was again associated with lower risk (HRQ5 vs Q1 = 0.37; 95% CI = 0.20‐0.68; Ptrend = .001), whereas higher total vitamin B6 intake was associated with higher risk (HRQ5 vs Q1 = 2.04; 95% CI = 1.02‐4.07; Ptrend = .04). Restricted cubic spline analyses showed a dose‐response inverse association between total vitamin B3 intake and HCC risk, and dose‐response positive association between total vitamin B6 intake and HCC risk. The study suggests that higher vitamin B3 intake is associated with lower HCC risk, whereas higher vitamin B6 intake is associated with increased risk.